New York, NYCIK 20544107 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
21 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Terns Pharmaceuticals Inc | 1.75M | $70.55M | 23.9% | −225.0K | Reduced |
| 2 | Cg Oncology Inc | 1.13M | $46.98M | 15.9% | 0 | Held |
| 3 | Urogen Pharma Ltd | 1.45M | $33.92M | 11.5% | +188.7K | Added |
| 4 | Trevi Therapeutics Inc |
| 2.14M |
| $26.85M |
| 9.1% |
| 0 |
| Held |
| 5 | Puma Biotechnology Inc | 4.13M | $24.58M | 8.3% | 0 | Held |
| 6 | Candel Therapeutics Inc | 2.58M | $14.58M | 4.9% | 0 | Held |
| 7 | Cybin Inc | 1.57M | $12.87M | 4.4% | +838.6K | Added |
| 8 | Verastem Inc | 1.47M | $11.34M | 3.8% | +689.7K | Added |
| 9 | Bicara Therapeutics Inc | 643.4K | $10.83M | 3.7% | 0 | Held |
| 10 | Protara Therapeutics Inc | 1.75M | $9.34M | 3.2% | 0 | Held |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio